Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease

Beneficial Microbes

Volumn 6, Issue 3, 2015, Pages 277-286

  Elian, S D A ^a   Souza, E L S ^a   Vieira, A T ^a   Teixeira, M M ^a   Arantes, R M E ^a   Nicoli, J R ^a   Martins, F S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Bifidobacterium infantis; Inflammatory bowel diseases; Inflammatory cytokines; Ulcerative colitis

Indexed keywords

CXCL1 CHEMOKINE; DEXTRAN SULFATE; DRINKING WATER; EOTAXIN; MUCIN; PROBIOTIC AGENT; SECRETORY IMMUNOGLOBULIN; IMMUNOGLOBULIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIUM INFANTIS; CONTROLLED STUDY; DISEASE ACTIVITY; EDEMA; EXPERIMENTAL MODEL; FEMALE; GLYCOPROTEIN SYNTHESIS; HISTOPATHOLOGY; INTESTINE; INTESTINE MUCOSA PERMEABILITY; LIVER PARENCHYMA; MORPHOMETRICS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTECTION; ULCERATIVE COLITIS; ANIMAL; BAGG ALBINO MOUSE; BIFIDOBACTERIUM; DISEASE MODEL; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; PHYSIOLOGY;

ANIMALS; BIFIDOBACTERIUM; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOGLOBULIN A; INFLAMMATORY BOWEL DISEASES; MICE; MICE, INBRED BALB C; PROBIOTICS;

EID: 84928530576     PISSN: 18762883     EISSN: 18762891     Source Type: Journal    
DOI: 10.3920/BM2014.0070     Document Type: Article

References (51)

1. Albert, E., Walker, J., Thiesen, A., Churchill, T. and Madsen, K., 2010. Cis-urocanic acid attenuates acute dextran sodium sulphate-induced intestinal inflammation. PLoS ONE 5: e13676.
2. Anezaki, K., Asakura, H., Honma, T., Ishizuka, K., Funakoshi, K., Tsukada, Y. and Narisawa, R., 1998. Correlations between interleukin-8, and myeloperoxidase or luminol-dependent chemiluminescence in inflamed mucosa of ulcerative colitis. Internal Medicine 37: 253-258.
3. Bennedsen, M., Stuer-Lauridsen, B., Danielsen, M. and Johansen, E., 2011. Screening for antimicrobial resistance genes and virulence factors via genome sequencing. Applied and Environmental Microbiology 77: 2785-2787.
4. Bibiloni, R., Fedorak, R.N., Tannock, G.W., Madsen, K.L., Gionchetti, P., Campieri, M., De Simone, C. and Sartor, R.B., 2005. VSL#3 probioticmixture induces remission in patients with active ulcerative colitis. American Journal of Gastroenterology 100: 1539-1546.
5. Bin-Nun, A., Bromiker, R., Wilschanski, M., Kaplan, M., Rudensky, B., Caplan, M. and Hammerman, C., 2005. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. Journal of Pediatrics 147: 192-196.
6. Buanne, P., Di Carlo, E., Caputi, L., Brandolini, L., Mosca, M., Cattani, F., Pellegrini, L., Biordi, L., Coletti, G., Sorrentino, C., Fedele, G., Colotta, F., Melillo, G. and Bertini, R., 2007. Crucial pathophysiological role of CXCR2 in experimental ulcerative colitis in mice. Journal of Leukocyte Biology 82: 1239-1246.
7. Carlson, M., Raab, Y., Peterson, C., Hällgren, R. and Venge, P., 1999. Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. American Journal of Gastroenterology 94: 1876-1883.
8. Chen, W., Paulus, B., Shu, D., Wilson, I. and Chadwick, V., 2001. Increased serum levels of eotaxin in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology 36: 515-520.
9. Cooper, H.S., Murthy, S.N., Shah, R.S. and Sedergran, D.J., 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory Investigation 6: 238-249.
10. Corrêa, N.B.O., Lima, F.M.L.S., Nicoli, J.R., Péret, L.A.F. and Penna, F.J., 2005. A randomized placebo-controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibioticassociated diarrhea in infants. Journal of Clinical Gastroenterology 39: 385-389.
11. Danese, S. and Fiocchi, C., 2011. Ulcerative colitis. New England Journal of Medicine 365: 1713-1725.
12. Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2002. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. Available at: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf.
13. Garcia Vilela, E., De Lourdes De Abreu Ferrari, M., Oswaldo Da Gama Torres, H., Guerra Pinto, A., Carolina Carneiro Aguirre, A., Paiva Martins, F., Marcos Andrade Goulart, E. and Sales Da Cunha, A., 2008. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scandinavian Journal of Gastroenterology 43: 842-848.
14. Garrido-Mesa, N., Utrilla, P., Comalada, M., Zorrilla, P., Garrido-Mesa, J., Zarzuelo, A., Rodríguez-Cabezas, M.E. and Gálvez, J., 2005. The association of minocycline and the probiotic Escherichia coli Nissle 1917 results in an additive beneficial effect in a DSS model of reactivated colitis in mice. Biochemical Pharmacology 82: 1891-1900.
15. Gionchetti, P., Rizzello, F., Helwig, U., Venturi, A., Lammers, K.M., Brigidi, P., Vitali, B., Poggioli, G., Miglioli, M. and Campieri, M., 2003. Prophylaxis of pouchitis onset with probiotic therapy: a doubleblind, placebo-controlled trial. Gastroenterology 124: 1202-1209.
16. Gionchetti, P., Rizzello, F., Venturi, A., Brigidi, P., Matteuzzi, D., Bazzocchi, G., Poggioli, G. and Campieri, M., 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305-309.
17. Guerra, P.V.P., Lima, L.N., Souza, T.C., Mazochi, V., Penna, F.J., Silva, A.M., Nicoli, J.R. and Guimarães, E.V., 2011. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World Journal of Gastroenterology 17: 3916-3921.
18. Guslandi, M., 2010. Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis. Journal of Clinical Gastroenterology 44: 385.
19. Guslandi, M., Giollo, P. and Testoni, P.A., 2003. A pilot trial of Saccharomyces boulardii in ulcerative colitis. European Journal of Gastroenterology and Hepatology 15: 697-698.
20. Guslandi, M., Mezzi, G., Sorghi, M. and Testoni, P.A., 2000. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Digestive Diseases and Sciences 45: 1462-1464.
21. Jacobs, S.E., Tobin, J.M., Opie, G.F., Donath, S., Tabrizi, S.N., Pirotta, M., Morley, C.J., Garland, S.M. and ProPrems Study Group, 2013. Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. Pediatrics 132, 1055-1062.
22. Jadhav, S.R., Shandilya, U.K. and Kansal, V.K., 2013. Exploring the ameliorative potential of probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum on dextran sodium sulphate induced colitis in mice. Journal of Dairy Research 80: 21-27.
23. Jeziorska, M., Haboubi, N., Schofield, P. and Woolley, D.E., 2001. Distribution and activation of eosinophils in inflammatory bowel disease using an improved immunohistochemical technique. Journal of Pathology 194: 484-492.
24. Kamada, N., Inoue, N., Hisamatsu, T., Okamoto, S., Matsuoka, K., Sato, T., Chinen, H., Hong, K.S., Yamada, T., Suzuki, Y., Suzuki, T., Watanabe, N., Tsuchimoto, K. and Hibi, T., 2005. Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflammatory Bowel Diseases 11: 455-463.
25. Keshavarzian, A., Fusunyan, R.D., Jacyno, M., Winship, D., MacDermott, R.P. and Sanderson, I.R., 1999. Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon. American Journal of Gastroenterology 94: 704-712.
26. Lampinen, M., Carlson, M., Sangfelt, P., Taha, Y., Thörn, M., Lööf, L., Raab, Y. and Venge, P., 2001. IL-5 and TNF-α participate in recruitment of eosinophils to intestinal mucosa in ulcerative colitis. Digestive Diseases and Sciences 46: 2004-2009.
27. Macpherson, A.J. and Harris, N.L., 2004. Interactions between commensal bacteria and the immune system. Nature Reviews Immunology 4: 478-485.
28. Martins, F.S., Silva, A.A., Vieira, A.T., Barbosa, F.H., Arantes, R.M., Teixeira, M.M. and Nicoli, J.R., 2009. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Archives of Microbiology 191: 623-630.
29. Martins, F.S., Vieira, A.T., Elian, S.D., Arantes, R.M., Tiago, F.C., Sousa, L.P., Araújo, H.R., Pimenta, P.F., Bonjardim, C.A., Nicoli, J.R. and Teixeira, M.M., 2013. Inhibition of tissue inflammation and bacterial translocation as one of the protective mechanisms of Saccharomyces boulardii against Salmonella infection in mice. Microbes and Infection 15: 270-279.
30. McGuckin, M.A., Lindén, S.K., Sutton, P. and Florin, T.H., 2011. Mucin dynamics and enteric pathogens. Nature Reviews Microbiology 9: 265-278.
31. Natsui, M., Kawasaki, K., Takizawa, H., Hayashi, S.I., Matsuda, Y., Sugimura, K., Seki, K., Narisawa, R., Sendo, F. and Asakura, H., 1997. Selective depletion of neutrophils by a monoclonal antibody. RP-3, suppresses dextran sulphate sodium-induced colitis in rats. Journal of Gastroenterology and Hepatology 12: 801-808.
32. Ofek Shlomai, N., Deshpande, G., Rao, S. and Patole, S., 2014. Probiotics for preterm neonates: what will it take to change clinical practice? Neonatology 105: 64-70.
33. Osman, N., Adawi, D., Ahrne, S., Jeppsson, B. and Molin, G., 2004. Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. Digestive Diseases and Sciences 49: 320-327.
34. Perše, M. and Cerar, A., 2012. Dextran sodium sulphate colitis mouse model: traps and tricks. Journal of Biomedicine and Biotechnology 2012: 718617.
35. Plein, K. and Hotz, J., 1993. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea-a pilot study. Zeitschrift für Gastroenterologie 31: 129-134.
36. Raab, Y., Fredens, K., Gerdin, B. and Hällgren, R., 1998. Eosinophil activation in ulcerative colitis: studies on mucosal release and localization of eosinophil granule constituents. Digestive Diseases and Sciences 43: 1061-1070.
37. Rembacken, B.J., Snelling, A.M., Hawkey, P.M., Chalmers, D.M. and Axon, A.T., 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. The Lancet 354: 635-639.
38. Sangfelt, P., Carlson, M., Thörn, M., Lööf, L. and Raab, Y., 2001. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. American Journal of Gastroenterology 96: 1085-1090.
39. Scapini, P., Lapinet-Vera, J.A., Gasperini, S., Calzetti, F., Bazzoni, F. and Cassatella, M.A., 2000. The neutrophil as a cellular source of chemokines. Immunological Reviews 177: 195-203.
40. Sociedade Brasileira da Ciência em Animais de Laboratório/Colégio Brasileiro de Experimentação Animal (SBCAL/COBEA), 2006. Legislação e ética. Available at: http://www.cobea.org.br.
41. Strath, M., Warren, D.J. and Sanderson, C.J., 1985. Detection of eosinophils using an eosinophil peroxidase assay. Its use as an assay for eosinophil differentiation factors. Journal of Immunological Methods 83: 209-215.
42. Uguccioni, M., Gionchetti, P., Robbiani, D.F., Rizzello, F., Peruzzo, S., Campieri, M. and Baggiolini, M., 1999. Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. American Journal of Pathology 155: 331-336.
43. Ukena, S.N., Singh, A., Dringenberg, U., Engelhardt, R., Seidler, U., Hansen, W., Bleich, A., Bruder, D., Franzke, A., Rogler, G., Suerbaum, S., Buer, J., Gunzer, F. and Westendorf, A.M., 2007. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE 2: e1308.
44. Vieira, A.T., Fagundes, C.T., Alessandri, A.L., Castor, M.G., Guabiraba, R., Borges, V.O., Silveira, K.D., Vieira, E.L., Gonçalves, J.L., Silva, T.A., Deruaz, M., Proudfoot, A.E., Sousa, L.P. and Teixeira, M.M., 2009. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. American Journal of Pathology 175: 2382-2391.
45. Vieira, A.T., Pinho, V., Lepsch, L.B., Scavone, C., Ribeiro, I.M., Tomassini, T., Ribeiro-dos-Santos, R., Soares, M.B., Teixeira, M.M. and Souza, D.G., 2005. Mechanisms of the anti-inflammatory effects of the natural secosteroids physalins in a model of intestinal ischaemia and reperfusion injury. British Journal of Pharmacology 146: 244-251.
46. Vieira, A.T., Teixeira, M.M. and Martins, F.S., 2013. The role of probiotics and prebiotics in inducing gut immunity. Frontiers in Immunology 4: 445.
47. Wirtz, S., Neufert, C., Weigmann, B. and Neurath, M.F., 2007. Chemically induced mouse models of intestinal inflammation. Nature Protocols 2: 541-546.
48. Xavier, R.J. and Podolsky, D.K., 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
49. Yan, Y., Kolachala, V., Dalmasso, G., Nguyen, H., Laroui, H., Sitaraman, S.V. and Merlin, D., 2009. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS ONE 4: e6073.
50. Yang, S.K., Choi, M.S., Kim, O.H., Myung, S.J., Jung, H.Y., Hong, W.S., Kim, J.H. and Min, Y.I., 2002. The increased expression of an array of C-X-C and C-C chemokines in the colonic mucosa of patients with ulcerative colitis: regulation by corticosteroids. American Journal of Gastroenterology 97: 126-132.
51. Zyrek, A.A., Cichon, C., Helms, S., Enders, C., Sonnenborn, U. and Schmidt, M.A., 2007. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cellular Microbiology 9: 804-816.